Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis

Author(s): Lucas Ribeiro dos Santos*, Marcio Luis Duarte, Maria Stella Peccin, Antônio Ricardo de Toledo Gagliardi, Tamara Melnik

Journal Name: Current Diabetes Reviews

Volume 17 , Issue 5 , 2021

Article ID: e101120187811
Become EABM
Become Reviewer
Call for Editor


Introduction: Hepatic steatosis is a frequent condition that afflicts, especially, obese and insulin-resistant patients. Diagnosis is usually made through imaging tests. Despite the high prevalence and risk of complications, there is no specific treatment approved, though a vast number of medications have been tested.

Objective: This study aimed to determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP- IV) in the treatment of NAFLD.

Methods: We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE, and LILACS, as well as reference lists of the included studies and grey literature; 9 studies were selected for inclusion.

Results: 7 studies were used for metanalysis for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83 (95% CI 35.23 to 13.57) at 3 months and MD -9.27 (95% CI 10.92 to -7.62) at 6 months of intervention, as well as a reduction of hepatic steatosis via MRI of SMD 0.10 (95% CI 0.31 to 0.50); the overall incidence of adverse events was very low. The studies were considered of low and very low quality by the GRADE evaluation.

Conclusion: Because of the overall poor quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.

Keywords: Dipeptidyl-Peptidase IV inhibitors, fatty liver, steatohepatitis, type 2 diabetes mellitus, obesity, systematic review.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 10 November, 2020
Article ID: e101120187811
Pages: 12
DOI: 10.2174/1573399816999201110195634
Price: $65

Article Metrics

PDF: 28